Vaxcellbio’s multiple myeloma treatment candidate ‘CAR-MIL’ chosen for the National New Drug 카지노 바카라 Project

[by Yu, Suin] Vaxcellbio announced on June 24 that it had signed an agreement with the Korea Drug 카지노 바카라 Fund (KDDF) for the 카지노 바카라 of CAR-MIL (chimeric antigen receptor-expressing bone marrow infiltrating lymphocytes) targeting BCMA (B-cell maturation antigen) for the treatment of multiple myeloma.

Under the agreement, Vaxcellbio will receive research and 카지노 바카라 funding over the next two years to support the 카지노 바카라 of its ‘BCMA-targeting CAR-MIL therapy for the treatment of multiple myeloma.’

According to Vaxcellbio, CAR-MIL is a therapeutic approach that involves the genetic modification of lymphocytes extracted from a patient’s bone marrow. It is being developed as a cell therapy candidate characterized by enhanced survival and persistence in the tumor microenvironment, along with maximized anticancer efficacy. In prior mouse models, the BCMA-targeting CAR-MIL experimental group demonstrated superior tumor-killing capacity and improved survival rates compared to the conventional CAR-T control group, while also exhibiting a favorable safety profile.

As part of this national new drug 카지노 바카라 project, Vaxcellbio aims to carry out non-clinical trials and obtain approval for its clinical trial plan (IND). The company also intends to address key challenges associated with current CAR-T therapies, including a complex manufacturing process, high production costs, and reduced efficacy due to treatment resistance.

The company notes that no bone marrow infiltrating lymphocyte therapy expressing BCMA CAR has yet been commercialized globally, positioning Vaxcellbio at the forefront of research and 카지노 바카라 (R&D) in this field.

“CAR-MIL is one of our company’s core technologies that has secured a distinct position in the multiple myeloma blood cancer treatment market,” said Lee Je-jung, CEO of Vaxcellbio. “Through our selection for the National New Drug 카지노 바카라 Project, we will lay the clinical trial foundation for the first CAR-MIL therapy in Korea and further solidify our leadership in the global market.”

The National New Drug 카지노 바카라 Project is a government-led R&D initiative established to strengthen the global competitiveness of the Korean pharmaceutical and biotechnology industries. The project provides comprehensive support throughout the entire new drug 카지노 바카라 cycle, aiming to reinforce the domestic R&D ecosystem for new drug 카지노 바카라 and to facilitate successful global commercialization outcomes.

“We hope that this research, based on an innovative immune cell therapy platform, will offer new hope to patients with intractable blood cancers who face limited treatment options. The fund will continue to actively support this outstanding technology to ensure it delivers meaningful outcomes on the global stage,” expressed Park Yeong-min, CEO of the Korea Drug 카지노 바카라 Fund (KDDF).